A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in ...
“I think there's a lot to be done and combination therapies, other drugs that can be instilled into this device. It's a bright future,” says Siamak Daneshmand, MD. In this video, Siamak Daneshmand, MD ...
Vibegron is the first beta-3 agonist approved for OAB symptoms in men treated for BPH, showing significant symptom improvement. The phase 3 COURAGE trial demonstrated significant reductions in ...
The ASPIRE trial showed SURE's noninferiority to URS in stone-free rate for nephrolithiasis treatment. SURE demonstrated superior stone clearance and residual stone volume outcomes, unaffected by ...
The series empowers surgeons to make informed family planning decisions through education, resources, and peer networking. Research indicates female surgeons face higher pregnancy complications and ...
In this interview, Michael S. Cookson, MD, MMHC, FACS, touches on the current and future applications of PSMA-PET imaging in prostate cancer. Cookson, who is a professor and the Donald D. Albers ...
What are the 5 stages of bladder health? We've talked a little bit about the Man vs Prostate campaign, and it's really important that it's built upon a principle of linguistic determinism. We really ...
“Some of the main implications for urologists is that the risk adapted utilization of BCG, which has been implemented as guidelines, should continue,” says Madison M. Wahlen. In this video, Madison M.
A panelist discusses how Non-muscle Invasive Bladder Cancer (NMIBC) treatment varies by risk stratification (low, intermediate, and high-risk), with BCG immunotherapy being standard for high-risk ...
"There are only 2 major organs you can't transplant: the brain and the bladder. So let's take care of the bladder," says Wayne Kuang, MD. In this video, Wayne Kuang, MD, gives an overview of the Man ...